Breaking News Instant updates and real-time market news.

AET

Aetna

$114.46

0.99 (0.87%)

, MRK

Merck

$63.90

1.13 (1.80%)

08:47
10/11/16
10/11
08:47
10/11/16
08:47

Aetna, Merck announce value-based contract for Januvia and Janumet

Aetna (AET) announced that it has entered into a value-based agreement with Merck (MRK) for the type 2 diabetes medications Januvia and Janumet. Under this agreement, Merck's rebates on Januvia and Janumet will be based in part on those products' contributions to helping Aetna's commercial member population with type 2 diabetes achieve or maintain treatment objectives. In a separate initiative, Merck is also collaborating with Aetna on AetnaCare, a new health approach which uses predictive analytics to identify target populations and proactively curate various health and wellness services that are available to each member. "Working with a patient's physicians and other caregivers, the program is designed to support treatment adherence, ensure that critical social support needs are met, and reinforce healthy lifestyle behaviors. The AetnaCare program will initially target patients with diabetes and hypertension in Mid-Atlantic markets," the companies stated. Merck has used its insights and experience to develop educational resources and tools to help address patient engagement, patient behavior and treatment adherence. Aetna will incorporate some of these resources from Merck's inventory into AetnaCare to support more effective patient self-management, the companies explained.

AET

Aetna

$114.46

0.99 (0.87%)

MRK

Merck

$63.90

1.13 (1.80%)

  • 25

    Oct

  • 06

    Nov

  • 10

    Nov

AET Aetna
$114.46

0.99 (0.87%)

09/29/16
PACS
09/29/16
DOWNGRADE
PACS
Underweight
Pacific Crest cuts Fitbit to sell, sees share downside to $11
Pacific Crest analyst Brad Erickson downgraded Fitbit (FIT) to Underweight from Sector Weight after his channel checks indicated that Charge 2, the company's flagship holiday product, is off to a slow start. Underweight is Pacific Crest's equivalent of a sell rating. Charge 2 inventory is accumulating in the channel and sell-through is below initial Blaze/Alta levels, Erickson tells investors in a research note. The analyst continues to believe that a large portion of Fitbit owners stop using the device within months. Further, he views the corporate wellness deal between Aetna (AET) and Apple (AAPL) as a "substantial negative" for Fitbit. Erickson sees downside to $11 for shares of Fitbit. The stock closed yesterday up 17c to $16.70.
09/22/16
EVER
09/22/16
INITIATION
Target $128
EVER
Buy
Aetna initiated with a Buy at Evercore ISI
Evercore ISI analyst Michael Newshel initiated Aetna with a Buy and a $128 price target.
08/25/16
COWN
08/25/16
NO CHANGE
COWN
Managed Care mergers unlikely to close, says Cowen
Cowen analyst Christine Arnold believes the current managed care mergers including Aetna (AET) and Humana (HUM) and Anthem (ANTM) and Cigna (CI) are unlikely to close. The analyst said the government's ability to appeal could extend the litigation process beyond the termination dates stipulated in the merger agreements. Arnold believes the Aetna/Humana merger has a better chance of closing relative to the Anthem/Cigna deal, but believes neither are likely to close.
08/22/16
LEER
08/22/16
NO CHANGE
LEER
Leerink less positive that Anthem challenge to DOJ lawsuit will be successful
Following a conference call with an anti-trust specialist, Leerink analyst Ana Gupte is less positive that the Anthem (ANTM) challenge to the lawsuit by the DOJ will be successful. The analyst says that the specialist views the obstacles to a defense by Anthem-Cigna (CI) to the anti-trust concerns as too numerous to result in a successful close. Further, the analyst believes that any favorable decision, however unlikely, on the merger close, will likely be appealed by the DOJ. Nonetheless, the lower likelihood of this defense being successful may improve the odds of a successful Aetna (AET)-Humana (HUM) defense, the analyst notes.
MRK Merck
$63.90

1.13 (1.80%)

10/10/16
JMPS
10/10/16
NO CHANGE
JMPS
Incyte treatment looking 'promising,' says JMP Securities
After reviewing recent data, JMP Securities analyst Liisa Bayko says that the combination of Incyte's (INCY) Epacadostat plus Merck's (MRK) Keytruda is "emerging as a promising treatment, potentially even best in class." The analyst says that the progression free survival rate of the combination in melanoma patients "is emerging to be quite competitive," while the efficacy rate in other solid tumors "seemed encouraging." The analyst raised her price target on Incyte to $110 from $100 and keeps an Outperform rating on the stock.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Market Perform
Merck 'steals the show' at ESMO with Keytruda data, says Leerink
Leerink analyst Seamus Fernandez said Merck (MRK) stole the show at ESMO with its Keytruda data and he continues to think the company will dominate first line lung cancer treatment for years to come in patients with 50%+ PDL1 expression. Additionally, he expects Merck to gain additional traction in the overall market, noting that confirmation that Keytruda is benefiting patients when combined with Alimta/carboplatin with Alimta maintenance raises the possibility Merck could compete broadly in the overall non-squamous patient population. However, Fernandez keeps a Market Perform rating on Merck, as he thinks its current valuation largely reflects improved growth prospects through 2020.
10/10/16
BMOC
10/10/16
NO CHANGE
BMOC
Merck should strengthen leadership in first line NSCLC, says BMO Capital
BMO Capital analyst Alex Arfaei says that upcoming data should strengthen Merck's (MRK) lead in 1L NSCLC. The analyst adds that the data could support off-label use of Merck's Keytruda in additional 1L NSCLC patients, and he says that the data "should be negative" for Bristol-Myers' (BMY) Opdivo drug. Arfaei keeps an Outperform rating on Merck and a Market Perform rating on Bristol-Myers.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.

TODAY'S FREE FLY STORIES

ILG

ILG

$18.88

-0.21 (-1.10%)

15:11
03/01/17
03/01
15:11
03/01/17
15:11
Options
Notable call spread in ILG after earnings were reported yesterday »

Notable call spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

  • 15

    Mar

  • 16

    Mar

PRGX

PRGX Global

$6.25

0.45 (7.76%)

15:10
03/01/17
03/01
15:10
03/01/17
15:10
Upgrade
PRGX Global rating change  »

PRGX Global upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDCE

PDC Energy

$67.59

-4.1 (-5.72%)

15:05
03/01/17
03/01
15:05
03/01/17
15:05
Upgrade
PDC Energy rating change  »

PDC Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Apr

  • 20

    Apr

JUNO

Juno Therapeutics

$24.04

0.64 (2.74%)

15:05
03/01/17
03/01
15:05
03/01/17
15:05
Options
Juno Therapeutics options imply 11.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 01

    Apr

SBGI

Sinclair Broadcast

$39.90

-0.05 (-0.13%)

15:01
03/01/17
03/01
15:01
03/01/17
15:01
Hot Stocks
Sinclair Broadcast acquires Tennis Media Company in up to $14M deal »

Sinclair Broadcast Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

PRGX

PRGX Global

$6.25

0.45 (7.76%)

15:01
03/01/17
03/01
15:01
03/01/17
15:01
Upgrade
PRGX Global rating change  »

PRGX Global upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXT

Textron

$49.46

2.16 (4.57%)

15:01
03/01/17
03/01
15:01
03/01/17
15:01
Options
Bullish flow in Textron as shares rally »

Bullish flow in Textron…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

NUS

Nu Skin

$49.41

-0.13 (-0.26%)

, EQY

Equity One

$31.20

-0.46 (-1.45%)

14:55
03/01/17
03/01
14:55
03/01/17
14:55
Hot Stocks
Breaking Hot Stocks news story on Nu Skin, Equity One »

Nu Skin to replace Equity…

NUS

Nu Skin

$49.41

-0.13 (-0.26%)

EQY

Equity One

$31.20

-0.46 (-1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REG

Regency Centers

$69.37

-0.98 (-1.39%)

, ENDP

Endo

$13.65

0.36 (2.71%)

14:55
03/01/17
03/01
14:55
03/01/17
14:55
Hot Stocks
Regency Centers to replace Endo in S&P 500 as of 3/2 open »

Regency Centers (REG) is…

REG

Regency Centers

$69.37

-0.98 (-1.39%)

ENDP

Endo

$13.65

0.36 (2.71%)

EQY

Equity One

$31.20

-0.46 (-1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

  • 14

    Mar

ENDP

Endo

$13.65

0.36 (2.71%)

, REG

Regency Centers

$69.37

-0.98 (-1.39%)

14:55
03/01/17
03/01
14:55
03/01/17
14:55
Hot Stocks
Breaking Hot Stocks news story on Endo, Regency Centers »

Endo to replace Regency…

ENDP

Endo

$13.65

0.36 (2.71%)

REG

Regency Centers

$69.37

-0.98 (-1.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

  • 14

    Mar

XOP

SPDR Oil Exploration and Production Fund

$38.88

1.0201 (2.69%)

14:51
03/01/17
03/01
14:51
03/01/17
14:51
Options
Hefty put spread in SPDR Oil Exploration and Production ETF »

Hefty put spread in SPDR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNST

Monster Beverage

$41.44

-0.65 (-1.54%)

14:50
03/01/17
03/01
14:50
03/01/17
14:50
Options
Monster Beverage options imply 9.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPXL

Impax

$14.25

-0.4 (-2.73%)

14:45
03/01/17
03/01
14:45
03/01/17
14:45
Downgrade
Impax rating change  »

Impax downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 06

    Mar

  • 14

    Mar

14:45
03/01/17
03/01
14:45
03/01/17
14:45
General news
Market remains at record levels in afternoon trading »

Stocks remain sharply…

GD

General Dynamics

$192.22

2.41 (1.27%)

14:43
03/01/17
03/01
14:43
03/01/17
14:43
Hot Stocks
General Dynamics boosts dividend to 84c per share, adds 10M shares to buyback »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

P

Pandora

$12.26

-0.125 (-1.01%)

, SIRI

Sirius XM

$5.09

-0.09 (-1.74%)

14:41
03/01/17
03/01
14:41
03/01/17
14:41
Periodicals
Liberty Media: Pandora is 'great product,' 'way undermonetized,' Bloomberg says »

Sirius XM (SIRI) CEO…

P

Pandora

$12.26

-0.125 (-1.01%)

SIRI

Sirius XM

$5.09

-0.09 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 06

    Mar

  • 19

    Mar

  • 22

    Mar

  • 23

    Mar

GNW

Genworth

$4.14

0.0501 (1.22%)

14:41
03/01/17
03/01
14:41
03/01/17
14:41
Conference/Events
Genworth to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

GD

General Dynamics

$192.08

2.27 (1.20%)

14:40
03/01/17
03/01
14:40
03/01/17
14:40
Hot Stocks
Breaking Hot Stocks news story on General Dynamics »

General Dynamics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$240.20

3.73 (1.58%)

, SPX

S&P 500

$2,399.94

36.3 (1.54%)

14:38
03/01/17
03/01
14:38
03/01/17
14:38
Technical Analysis
S&P 500 crosses 2400 for the first time »

The S&P 500 (SPX) has…

SPY

SPDR S&P 500 ETF Trust

$240.20

3.73 (1.58%)

SPX

S&P 500

$2,399.94

36.3 (1.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KAR

KAR Auction

$45.02

0.2 (0.45%)

14:33
03/01/17
03/01
14:33
03/01/17
14:33
Hot Stocks
KAR Auction appoints Howse as Chief Commercial Officer »

KAR Auction Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

  • 14

    Mar

  • 15

    Mar

APD

Air Products

$142.94

2.47 (1.76%)

, MPC

Marathon Petroleum

$51.23

1.63 (3.29%)

14:30
03/01/17
03/01
14:30
03/01/17
14:30
Hot Stocks
Air Products says wins additional Marathon Petroleum supply contract »

Air Products (APD)…

APD

Air Products

$142.94

2.47 (1.76%)

MPC

Marathon Petroleum

$51.23

1.63 (3.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

CETX

Cemtrex

$3.54

-0.28 (-7.33%)

14:29
03/01/17
03/01
14:29
03/01/17
14:29
Hot Stocks
Cemtrex announces stock buyback of over 200K shares »

Cemtrex announced today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDCA

MDC Partners

$8.75

-0.1 (-1.13%)

14:27
03/01/17
03/01
14:27
03/01/17
14:27
Hot Stocks
MDC Partners received subpoena from Department of Justice »

MDC Partners disclosed in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 06

    Mar

BUD

AB InBev

$109.93

0.44 (0.40%)

, KR

Kroger

$32.09

0.285 (0.90%)

14:26
03/01/17
03/01
14:26
03/01/17
14:26
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BUD

AB InBev

$109.93

0.44 (0.40%)

KR

Kroger

$32.09

0.285 (0.90%)

BURL

Burlington Stores

$87.24

-1.77 (-1.99%)

JOY

Joy Global

$28.20

0.005 (0.02%)

ANF

Abercrombie & Fitch

$11.25

-0.51 (-4.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 02

    Mar

  • 07

    Mar

  • 19

    Mar

14:25
03/01/17
03/01
14:25
03/01/17
14:25
General news
Treasury Action: yields remained elevated »

Treasury Action: yields…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.